The clinical trial with sitagliptin individuals with T2DM, which is powered to assess the capacity of this DPP4 inhibitor on SDF-1, demonstrated that sitagliptin remarkably suppresses SDF-1 degradation (66). The gene discussed is CXCL12; the disease is type 2 diabetes mellitus.